Leap Therapeutics

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Sept. 24, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 shares of its common stock, which includes the sale of an additional 4,740,000 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional shares, and of pre-funded warrants to purchase 8,771,928 shares of its common stock.

Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $2.849 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.

Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., Sept. 21, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.

Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Entasis Therapeutics Holdings Inc

Reed's

Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Making Money With Penny Stocks During a Stock Market Crash

Leap Therapeutics (NASDAQ:LPTX) shares are trading higher after the company announced it presented updated results for its DKN-01 plus tislelizumab which showed "compelling" activity in first-line patients with gastric, gastroesophageal junction cancer. Leap Therapeutics' stock is trading up 38.86% to a price of $2.68.

Why Leap Therapeutics Shares Are Trading Higher Today

Astra Space

Luokung Technology Corp

Momentus

Redwire Corp

Virgin Galactic

Spire Global

Space stocks are taking off on Thursday and it's all thanks to Elon Musk's SpaceX reaching a major milestone for commercial space travel. The post Space Stocks: Why SPIR, ASTR, MNTS, RDW and SPCE Are Getting a Boost Today appeared first on InvestorPlace.

Space Stocks: Why SPIR, ASTR, MNTS, RDW and SPCE Are Getting a Boost Today

Leap Therapeutics (LPTX) stock is on the move today following an update from the biotechnology company for recent clinical trial results. The post LPTX Stock: What Leap Therapeutics Investors Are Clicking Their Heels About Today appeared first on InvestorPlace.

LPTX Stock: What Leap Therapeutics Investors Are Clicking Their Heels About Today

The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 27% during intraday trading today. This is why it happened.

LPTX Stock: Why It Significantly Increased Today

Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ). The data were presented at the European Society for Medical Oncology (ESMO21) Congress.

Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer

CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.

Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

Yamana Gold

Ideanomics Inc

Finding trending penny stocks can be a great strategy to use, here's three to watch The post 3 Top Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks to Watch That Are Trending Right Now

This company has announced that it will be presenting promising data and shares of LPTX stock have taken a leap. The post LPTX Stock: Why Leap Therapeutics Just Soared 30% to Start the Day appeared first on InvestorPlace.

LPTX Stock: Why Leap Therapeutics Just Soared 30% to Start the Day

Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company's presentation of new data from the first-line cohort of the DisTinGuish study. The Phase 2a trial is evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ).

Why Are Leap Therapeutics Shares Trading Higher On Monday?

The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased over 20% pre-market. This is why it happened.

LPTX Stock: Why It Increased Today

CAMBRIDGE, Mass., Sept. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.

Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress

Hepion Pharmaceuticals Inc

Nymox Pharmaceutical

Verastem

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

CAMBRIDGE, Mass., Sept. 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of 7.69% and 0.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Leap Therapeutics, Inc. (LPTX) Reports Q2 Loss

CAMBRIDGE, Mass., Aug. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.

Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation

Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Leap Therapeutics, Inc. (LPTX) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's Ltd.

Leap Therapeutics to Present at the ESMO 2021 Virtual Congress

Leap Therapeutics, Inc. (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 19.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Leap Therapeutics, Inc. (LPTX)

CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference

Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -9.09% and -3.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Leap Therapeutics Stock (LPTX)